Center for Nuclear Medicine (U.I.E.A.S.T), South Campus, Panjab University, Sector 25, Chandigarh 160014, India.
Department of Microbiology, South Campus, Panjab University, Sector 25, Chandigarh 160014, India.
Virus Res. 2022 Sep;318:198853. doi: 10.1016/j.virusres.2022.198853. Epub 2022 Jun 28.
COVID-19 pandemic caused by the Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) has inflicted a global health challenge. Although the overwhelming escalation of mortality seen during the initial phase of the pandemic has reduced, emerging variants of SARS-CoV-2 continue to impact communities worldwide. Several studies have highlighted the association of gene specific epigenetic modifications in host cells with the pathogenesis and severity of the disease. Therefore, alongside the investigations into the virology and pathogenesis of SARS-CoV-2 infection, understanding the epigenetic mechanisms related to the disease is crucial for the rational design of effective targeted therapies. Here, we discuss the interaction of SARS-CoV-2 with the various epigenetic regulators and their subsequent contribution to the risk of disease severity and dysfunctional immune responses. Finally, we also highlight the use of epigenetically targeted drugs for the potential therapeutic interventions capable of eliminating viral infection and/or build effective immunity against it.
由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的 COVID-19 大流行给全球带来了健康挑战。尽管大流行初期死亡率的急剧上升已经有所缓解，但 SARS-CoV-2 的新变种仍在继续影响全球各地的社区。多项研究强调了宿主细胞中基因特异性表观遗传修饰与疾病的发病机制和严重程度之间的关联。因此，除了对 SARS-CoV-2 感染的病毒学和发病机制进行研究外，了解与疾病相关的表观遗传机制对于合理设计有效的靶向治疗至关重要。在这里，我们讨论了 SARS-CoV-2 与各种表观遗传调节剂的相互作用，以及它们随后对疾病严重程度和功能失调的免疫反应风险的贡献。最后，我们还强调了使用针对表观遗传的药物进行潜在的治疗干预的可能性，这些干预措施能够消除病毒感染和/或建立有效的免疫反应。
